EventsThe 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response
Published
This submission belongs to the session 8. Poster of the event The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response
Published date
29 Jan, 2021
Citation
Aleksey V Belikov, Sergey V Leonov, Alexey D Vyatkin, Danila V Otnykov, The extent of consequential DNA damage in human tumors from TCGA PanCanAtlas, in Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response, 1 February–14 February 2021, MDPI: Basel, Switzerland, doi: 10.3390/IECC2021-09202
Share
Email
Facebook
Twitter
LinkedIn

The extent of consequential DNA damage in human tumors from TCGA PanCanAtlas

Aleksey V Belikov 1
Alexey D Vyatkin 2
Danila V Otnykov 3
1. Laboratory of Innovative Medicine, School of Biological and Medical Physics, Moscow Institute of Physics and Technology, Russia
2. Moscow Institute of Physics and Technology
3. School of Biological and Medical Physics, Moscow Institute of Physics and Technology
4. Laboratory of Innovative Medicine, School of Biological and Medical Physics, Moscow Institute of Physics and Technology
Abstract

The DNA damage is crucial for the emergence of cancer cells. If the DNA damage response is defective, the DNA damage is converted to fixed mutations. Some of these mutations drive tumorigenesis and are called driver mutations. However, the extent of consequential DNA damage per tumor, i.e. the number of various kinds of driver mutations, is not known. We have utilized the largest database of human cancer mutations – TCGA PanCanAtlas, multiple popular algorithms for cancer driver prediction and several custom scripts to estimate the number of various kinds of driver mutations in primary tumors. We have found that there are on average 19.6 driver mutations per patient’s tumor, of which 2.4 are hyperactivating SNA mutations in oncogenes, 9.2 are CNA amplifications of oncogenes, 0.6 have both in the same oncogene, 0.2 are homozygous inactivating SNA mutations in tumor suppressors, 1.1 have inactivating SNA mutation in one allele and CNA deletion in the other allele of a tumor suppressor, 1.5 are driver chromosome losses, 2 are driver chromosome gains, 1 is driver chromosome arm loss, and 1.6 are driver chromosome arm gains. The number of driver mutations per tumor increased with age, from 12.5 for <25 y.o. to 23.6 for >85 y.o. There was no big difference between genders (19.9 in males vs 19.2 in females). The number of driver mutations per tumor varied strongly between cancer types, from 1.5 in thyroid carcinoma to 43 in lung squamous cell carcinoma. Overall, our results provide valuable insights into the extent of functional DNA damage in tumors.

Keywords
DNA damage
driver mutation
SNA
CNA
aneuploidy
chromosome
arm
gain
loss
tumorigenesis
carcinogenesis
TCGA
PanCanAtlas
oncogene
tumor suppressor
Manuscript
Poster
MDPI conference.pdf
Targeting the DNA repair enzyme APE1 in cancer therapy
RAD50 loss of function variants in the zinc hook domain associated with higher risk of familial esophageal squamous cell carcinoma